Is a Third Dose of Measles-mumps-rubella-(Varicella) Vaccine (MMR(V)) Vaccine Beneficial for the Adult Population in Alberta?

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Women who are pregnant and have undergone routine prenatal screening for rubella antibodies.

Locations
Other Locations
Canada
University of Alberta
RECRUITING
Edmonton
Contact Information
Primary
Carmen Charlton, PhD
carmen.charlton@albertahealthservices.ca
1 (780) 407-8975
Backup
Michael H Mengel
mmengel@ualberta.ca
17804925943
Time Frame
Start Date: 2024-11-09
Estimated Completion Date: 2026-02-28
Participants
Target number of participants: 200
Treatments
Women with low rubella antibodies
Women with rubella antibodies \<10 IU/mL
Women with high rubella antibodies
Women with rubella antibodies ≥10 IU/mL
Sponsors
Collaborators: Merck Canada Inc.
Leads: University of Alberta

This content was sourced from clinicaltrials.gov